Search
Displaying 221–230 of 661 for “retinal diseases”
-
Ophthotech to Boost Development of Gene Therapy for Best Disease
Research NewsOphthotech Corporation, a biopharmaceutical company focused on the development of therapies for orphan retinal diseases and age-related macular degeneration, has announced an evolving, commercial partnership with the University of Pennsylvania and University of Florida to develop a gene therapy for Best disease caused by BEST1 mutations.
-
Information for Newly Diagnosed Patients and their Loved Ones
-
Call to Action: Ask Congress to Support $1 Billion in Eye Research
Research NewsCall to Action: Ask Congress to Support $1 Billion in Eye Research
-
Leber Congenital Amaurosis (LCA)
DiseaseLCA is a group of inherited retinal diseases causing blindness or severe vision loss in early childhood.
-
SparingVision Formed to Advance Sight-Saving Protein for RP
Research NewsSparingVision received a €300,000 award known as the Honor Prize from the French Ministry of Research. The award is given to new, innovative companies in France competing in a national contest.
-
A Change in Identity Might Someday Save Vision
Research NewsBy changing the identity of cells in the retina–namely rods–researchers may someday be able to slow or halt vision loss for those with retinitis pigmentosa (RP) and other related conditions.
-
Inspired by Progress in Usher Syndrome Research
Research NewsMark Pennesi, M.D., Ph.D., a Foundation-funded clinical researcher at the Casey Eye Institute, discusses the first human study of gene therapy for Usher syndrome type 1B.
-
VISIONS 2014 — My Retina Tracker: Track Your Vision and Drive the Research
Research NewsThe powerful and secure system enables patients to keep track of their clinical care and vision changes. At the same time, it enables scientists to search the “de-identified” (i.e., anonymous) patient information to study conditions and identify targets for treatments, preventions and cures.
-
Proving a Vision-Saving Treatment Works
Research NewsThe information gleaned from ProgSTAR will be of enormous value in designing future clinical trials for Stargardt disease treatments.
